Welcome to our dedicated page for Parnell Pharmace news (Ticker: PARNF), a resource for investors and traders seeking the latest updates and insights on Parnell Pharmace stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Parnell Pharmace's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Parnell Pharmace's position in the market.
Summary not available.
Parnell Pharmaceuticals Holdings Ltd (OTC PINK:PARNF) has announced its Annual General Meeting (AGM) set for April 6, 2023, at 8:30 a.m. Australian Eastern Standard Time. The meeting will occur at the company’s headquarters in Alexandria, Australia. The agenda includes a vote on the buyback of shares from Mr. Robert Joseph and Mrs. Kate Joseph as part of a Settlement and Mutual Release Agreement. Shareholders can attend in person or vote via proxy. Further details are provided in the Notice of AGM and Explanatory Memorandum. The company encourages all shareholders to participate in the voting process.
Parnell Pharmaceuticals Holdings Ltd (OTC Pink: PARNF) announced an extension of its rights offering, now set to expire on January 11, 2023. This offering aims to raise approximately US$4.0 million in gross proceeds. The original expiration date was January 5, 2023. All other terms of the offering remain unchanged. The securities will be offered in a private placement under Section 4(a)(2) of the Securities Act, highlighting that they are not registered and cannot be sold in the U.S. without proper registration or exemptions.
Parnell Pharmaceuticals Holdings Ltd (OTC Pink: PARNF) has initiated a backstopped rights offering to raise approximately US$4.0 million. Shareholders as of December 6, 2022, can subscribe to purchase shares at US$0.075 each during the offering period from December 6, 2022 to January 5, 2023. The offering is fully backed by DW Healthcare Partners, which will purchase any unclaimed shares. Parnell retains the right to modify or cancel the offering. This private placement is not registered under U.S. securities laws and does not constitute an offering.
Parnell Pharmaceuticals Holdings Ltd (PARNF) announced a $4.0 million backstopped rights offering for qualifying shareholders, set to occur on December 6, 2022. The offering allows shareholders to purchase shares at $0.075 each, between December 6, 2022, and January 5, 2023. DW Healthcare Partners will backstop the offering, ensuring all shares are purchased if not fully subscribed. This offering is not registered with the SEC and will occur under private placement regulations.
Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF) announced its Annual General Meeting (AGM) scheduled for July 15, 2022, at 8:30 a.m. AEST. The meeting will take place at the company's headquarters in Alexandria, Australia. Key agenda items include reviewing financial statements for the year ended December 31, 2021, the ratification of the auditor, and the re-election of director Eric Moore. Shareholders are encouraged to attend in person or vote by proxy, with details provided in the Notice of AGM.
Parnell Pharmaceuticals Holdings Ltd (OTC PINK:PARNF) announced its Annual General Meeting (AGM) scheduled for August 5, 2021, at 8:30 a.m. AEST. The meeting will take place in person at the company's headquarters in Alexandria, Australia. Shareholders will review the financial statements for the year ending December 31, 2020, ratify the auditor's appointment, and re-elect Dr. Alan Bell as director. A proxy form is available for those unable to attend. Links to the full AGM notice and financial statements are provided.
DW Healthcare Partners (DWHP) has successfully completed its investment in Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF), a leading manufacturer of animal health pharmaceuticals. Established over 50 years ago in Australia, Parnell specializes in sterile injectables. The partnership aims to accelerate growth and expand Parnell's product portfolio, leveraging DWHP's healthcare expertise. This strategic investment signifies a major milestone in Parnell's long-term strategy, enhancing its financial foundation and governance through the addition of DWHP executives to its Board of Directors.
